Goldman Sachs tips BHP shares as a buy

Goldman's expects iron ore to make up around 65% of group EBITDA in 2019 it also suggested BHP could increase total oil production by 50% come FY 2030.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A lot of SMSF and institutional investors have done well holding BHP Group Ltd (ASX: BHP) shares over the last 12 months.

Not only is the stock up around 17 per cent but BHP has also paid out A$1.92 per share plus full franking credits to income-hungry investors. That equals a term-deposit thumping 5.1% yield at today's share price of $37.50. In addition it completed a US$5.2 billion share buy-back after it sold its onshore U.S. shale assets to further boost total shareholder returns.

According to an October 30 2019 research note out of Goldman Sachs there could be more upside ahead for BHP, with iron ore prices forecast to average US$86 a tonne over 2020.

While Goldman's expects iron ore to make up around 65% of group EBITDA in 2019 it also suggested BHP could increase total oil production by 50% come FY 2030.

Goldman's has a target price of $39.40 on BHP shares. It also has a buy rating on Rio Tinto Limited (ASX: RIO) shares.

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man looking at his laptop and thinking.
Materials Shares

Rio Tinto shares charge higher after Glencore merger collapses

The parties couldn't come to an agreement.

Read more »

a group of doctors and medical staff in uniform high five in celebration in a hospital setting
Share Market News

Neuren Pharmaceuticals kicks off Phase 3 trial in rare syndrome

Neuren Pharmaceuticals shares are on watch after dosing began in its key Phase 3 trial for Phelan-McDermid syndrome.

Read more »

A business person directs a pointed finger upwards on a rising arrow on a bar graph.
Broker Notes

Top broker forecasts another 83% upside for this outperforming ASX All Ords tech stock

A leading broker expects outsized gains from this ASX All Ords tech stock in 2026. But why?

Read more »

ASX share investor holding up hand in stop motion
Share Market News

Rio Tinto confirms no merger with Glencore after review

Rio Tinto has announced it won't pursue a merger with Glencore, reaffirming its focus on long-term value for shareholders.

Read more »

Two plants grow in jars filled with coins.
Growth Shares

2 excellent ASX All Ords stocks I'd buy today

These businesses are far too cheap, in my opinion.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Opinions

2 ASX shares that could turn $100,000 into $1 million

These ASX businesses are well-positioned for great growth over the next few years, and beyond.

Read more »

Shot of a young businesswoman looking stressed out while working in an office.
Share Market News

5 things to watch on the ASX 200 on Friday

It looks set to be a tough finish to the week for Aussie investors.

Read more »

A neon sign says 'Top Ten'.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors lost some of this week's mojo this Thursday.

Read more »